AlphAIAlphAI — Financial news for AI agents
investing.comOCT 212 min read$IBRX

ImmunityBio completes database lock for bladder cancer trial

ImmunityBio (NASDAQ:IBRX) completed database lock for Cohort A of its QUILT-2.005 trial, evaluating ANKTIVA with BCG vs. BCG alone in BCG-naïve bladder cancer patients. Interim analysis showed longer complete response duration with the combination. Final results and FDA submission expected in Q4 2026. The trial enrolled 366 patients across 110 sites.

Original reporting
investing.com
Published Oct 21, 2026, 11:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$IBRX
Bullish
high confidence
Mentioned
$IBRX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IBRXBullishMed
01

Why it matters

The database lock removes a procedural hurdle, allowing the company to focus on data analysis and filing plans, which could drive the stock higher ahead of the November readout.

02

Market read

A clear trial milestone for a biotech can move the stock as investors anticipate data; relevance is moderate to high for IBRX.

03

What to watch

Regulatory timeline and potential competition from other NMIBC therapies.

Relevance 8/10Novelty 8/10Timing: today

Background

ImmunityBio (NASDAQ:IBRX) is developing ANKTIVA, a therapy combined with BCG for bladder cancer. The QUILT-2.005 trial evaluates its efficacy in BCG‑naïve patients.

Company-level read

Ticker impact

$IBRXBullishHigh confidence
Context

ImmunityBio announced completion of database lock for Cohort A of its QUILT-2.005 bladder cancer trial, a new milestone before topline results.

Expected impact

potential upside as investors price in upcoming positive readout

Evidence & confidence

Biotech stocks often rally on clear trial progress; no new data yet but the milestone removes a delay risk.

Market effects

Sector

May boost sentiment for bladder cancer immunotherapy peers.

Regional

Limited to US biotech sector.

Global

Minor global impact, confined to oncology biotech space.

Counterpoint

What could challenge this read

If the interim data were not as strong as implied, the trial could still miss endpoints, limiting upside.

Key entities

  • company
    ImmunityBio, Inc.

    Biotech firm developing ANKTIVA for bladder cancer.

  • regulator
    FDA

    U.S. agency overseeing trial data and future approval.

Read at source← All news

StoryImmunityBio completes database lock for ANKTIVA bladder cancer trial, results due in November

Also covered by

1 outlet

Related articles

NOV 4
$IBRXMedAI 8/10

ImmunityBio, Inc.: ImmunityBio Announces First Patients in Europe Treated with ANKTIVA Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

ImmunityBio (NASDAQ: IBRX) announced the first European patients treated with ANKTIVA plus BCG for BCG-unresponsive bladder cancer. The treatment received conditional marketing authorization from the European Commission in February 2026. Accord Healthcare and Uniphar support commercialization and distribution across Europe.

finanznachrichten.de2 min
NOV 4
HighAI 8/10

ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

ImmunityBio has begun treating the first patients in Europe with ANKTIVA® plus BCG for BCG-unresponsive non-muscle invasive bladder cancer. The treatment received conditional marketing authorization from the European Commission in February 2026. Accord Healthcare and Uniphar are supporting commercialization and distribution efforts across Europe.

stocktitan.net2 min
OCT 26
$IBRXMedAI 9/10

Expanded Use for ImmunityBio Drug

ImmunityBio Inc. received FDA approval for expanded use of Anktiva to treat a more common form of bladder cancer, months ahead of schedule. The stock rose 4% on the news but has since fallen. Anktiva was initially approved in April 2024 for a rare form of bladder cancer. The FDA had rejected an earlier expanded use application but approved it in October 2024.

labusinessjournal.com3 min
OCT 22
$IBRXLowAI 8/10

ImmunityBio (IBRX): November ANKTIVA Trial Results Could Support Expanded FDA Filing?

ImmunityBio (IBRX) completed the database lock for its QUILT-2.005 trial, evaluating ANKTIVA plus BCG in BCG-naïve NMIBC patients. An FDA-requested interim analysis showed a statistically significant longer duration of complete response with the combination. Topline results are expected in November 2026, with a supplemental Biologics License Application planned for Q4 2026, according to the company.

rttnews.com1 min
OCT 21
$IBRXMedAI 8/10

IBRX Stock Rises: ImmunityBio Expects November Results For Anktiva Bladder Cancer Trial

ImmunityBio (IBRX) announced the completion of data collection for a 366-patient trial of ANKTIVA plus BCG in non-muscle invasive bladder cancer, with final results expected in November. The company reported a statistically significant interim analysis and plans to submit a supplemental Biologics License Application to the FDA in Q4 2026. IBRX shares rose 2% on the news.

stocktwits.com2 min